X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs LUPIN LTD - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA LUPIN LTD CIPLA/
LUPIN LTD
 
P/E (TTM) x 40.6 28.3 143.6% View Chart
P/BV x 3.7 3.0 126.3% View Chart
Dividend Yield % 0.5 0.6 80.8%  

Financials

 CIPLA   LUPIN LTD
EQUITY SHARE DATA
    CIPLA
Mar-18
LUPIN LTD
Mar-18
CIPLA/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs6631,465 45.3%   
Low Rs479727 65.9%   
Sales per share (Unadj.) Rs189.0349.6 54.1%  
Earnings per share (Unadj.) Rs17.65.6 316.6%  
Cash flow per share (Unadj.) Rs34.029.6 115.0%  
Dividends per share (Unadj.) Rs3.005.00 60.0%  
Dividend yield (eoy) %0.50.5 115.2%  
Book value per share (Unadj.) Rs176.7300.3 58.8%  
Shares outstanding (eoy) m805.12452.08 178.1%   
Bonus/Rights/Conversions ESOPESOPS-  
Price / Sales ratio x3.03.1 96.3%   
Avg P/E ratio x32.5197.2 16.5%  
P/CF ratio (eoy) x16.837.1 45.3%  
Price / Book Value ratio x3.23.6 88.5%  
Dividend payout %17.190.0 19.0%   
Avg Mkt Cap Rs m459,724495,502 92.8%   
No. of employees `00023.617.0 138.5%   
Total wages/salary Rs m26,90128,647 93.9%   
Avg. sales/employee Rs Th6,446.19,273.6 69.5%   
Avg. wages/employee Rs Th1,139.41,681.0 67.8%   
Avg. net profit/employee Rs Th600.0147.4 406.9%   
INCOME DATA
Net Sales Rs m152,193158,042 96.3%  
Other income Rs m3,5771,504 237.9%   
Total revenues Rs m155,769159,545 97.6%   
Gross profit Rs m28,26431,475 89.8%  
Depreciation Rs m13,22810,859 121.8%   
Interest Rs m1,1422,044 55.9%   
Profit before tax Rs m17,47020,076 87.0%   
Minority Interest Rs m0-71 0.0%   
Prior Period Items Rs m-2835 -79.0%   
Extraordinary Inc (Exp) Rs m-775-14,644 5.3%   
Tax Rs m2,5012,885 86.7%   
Profit after tax Rs m14,1662,513 563.8%  
Gross profit margin %18.619.9 93.2%  
Effective tax rate %14.314.4 99.6%   
Net profit margin %9.31.6 585.5%  
BALANCE SHEET DATA
Current assets Rs m108,141122,095 88.6%   
Current liabilities Rs m38,32250,956 75.2%   
Net working cap to sales %45.945.0 101.9%  
Current ratio x2.82.4 117.8%  
Inventory Days Days9785 114.7%  
Debtors Days Days74120 62.0%  
Net fixed assets Rs m109,411129,876 84.2%   
Share capital Rs m1,610904 178.1%   
"Free" reserves Rs m140,682134,866 104.3%   
Net worth Rs m142,292135,771 104.8%   
Long term debt Rs m36,62164,245 57.0%   
Total assets Rs m228,606263,054 86.9%  
Interest coverage x16.310.8 150.5%   
Debt to equity ratio x0.30.5 54.4%  
Sales to assets ratio x0.70.6 110.8%   
Return on assets %6.71.7 386.6%  
Return on equity %10.01.9 537.9%  
Return on capital %10.03.7 267.6%  
Exports to sales %32.80-   
Imports to sales %00-   
Exports (fob) Rs m49,883NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m51,69153,141 97.3%   
Fx outflow Rs m21,03319,335 108.8%   
Net fx Rs m30,65833,807 90.7%   
CASH FLOW
From Operations Rs m14,62817,512 83.5%  
From Investments Rs m-8,540-14,073 60.7%  
From Financial Activity Rs m-3,855-14,921 25.8%  
Net Cashflow Rs m2,431-11,482 -21.2%  

Share Holding

Indian Promoters % 16.0 46.6 34.3%  
Foreign collaborators % 20.8 0.2 10,400.0%  
Indian inst/Mut Fund % 12.2 11.3 108.0%  
FIIs % 23.7 31.9 74.3%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 10.1 259.4%  
Shareholders   161,166 98,259 164.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   GLENMARK PHARMA  J.B.CHEMICALS  MERCK LTD  DIVIS LABORATORIES  FULFORD INDIA  

Compare CIPLA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

LUPIN LTD 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of LUPIN LTD for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of LUPIN LTD. Also includes updates on the valuation of LUPIN LTD.

LUPIN LTD Announces Quarterly Results (1QFY19); Net Profit Up 21.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, LUPIN LTD has posted a net profit of Rs 4 bn (up 21.3% YoY). Sales on the other hand came in at Rs 26 bn (up 3.2% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Sep 21, 2018 (Close)

TRACK CIPLA

CIPLA - BIOCON LTD COMPARISON

COMPARE CIPLA WITH

MARKET STATS